Articles
Ideas shaping biotechnology growth—commercial leadership, launch strategy, and rare disease insights from PharmaKonsult.
What Does It Cost to Build a Commercial Organization for an Emerging Biotech?
Commercialization cost is not a sales-force line item. It is the full operating model required for patients to start therapy.
Read ArticleWhy Commercialization Should Influence Clinical Development
Clinical programs create the science. Commercial thinking determines whether that science can become a therapy patients can actually receive.
Read Article12 Commercial Questions Every Biotechnology Board Should Ask Before Launch
Boards do not need to manage the launch. They do need enough commercial visibility to understand whether management has identified the major risks.
Read ArticleWhy Centers of Excellence Matter in Rare Disease Commercialization
Rare disease markets are often defined by where expertise is concentrated. Understanding Centers of Excellence can materially change commercialization strategy.
Read ArticleWhen Should an Emerging Biotech Bring Commercial Leadership Into the Organization?
The key question is not how many months before launch to hire a CCO—it is when decisions require experienced commercial leadership.
Read ArticleCommercial Due Diligence for Biotechnology Assets: Look Beyond the Forecast
Effective commercial due diligence focuses on the assumptions connecting clinical performance to commercial adoption—not spreadsheet precision alone.
Read ArticleWhy Market Access Planning Must Start Before FDA Approval
Approval answers whether a product can be made available. It does not answer whether patients can realistically receive it.
Read ArticleShould an Emerging Biotech Commercialize Independently or Partner?
Neither strategy is universally correct. The decision should begin with a realistic understanding of what commercialization actually requires.
Read Article